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Abstract
Proteomic profiling of the estrogen/tamoxifen-sensitive MCF-7 cell line and its partially sensitive (MCF-7/LCC1) and fully
resistant (MCF-7/LCC9) variants was performed to identify modifiers of endocrine sensitivity in breast cancer. Analysis of the
expression of 120 paired phosphorylated and non-phosphorylated epitopes in key oncogenic and tumor suppressor
pathways revealed that STAT1 and several phosphorylated epitopes (phospho-STAT1(Tyr701) and phospho-STAT3(Ser727))
were differentially expressed between endocrine resistant and parental controls, confirmed by qRT-PCR and western
blotting. The STAT1 inhibitor EGCG was a more effective inhibitor of the endocrine resistant MCF-7/LCC1 and MCF-7/LCC9
lines than parental MCF-7 cells, while STAT3 inhibitors Stattic and WP1066 were equally effective in endocrine-resistant and
parental lines. The effects of the STAT inhibitors were additive, rather than synergistic, when tested in combination with
tamoxifen in vitro. Expression of STAT1 and STAT3 were measured by quantitative immunofluorescence in invasive breast
cancers and matched lymph nodes. When lymph node expression was compared to its paired primary breast cancer
expression, there was greater expression of cytoplasmic STAT1 (,3.1 fold), phospho-STAT3(Ser727) (,1.8 fold), and STAT5
(,1.5 fold) and nuclear phospho-STAT3(Ser727) (,1.5 fold) in the nodes. Expression levels of STAT1 and STAT3 transcript
were analysed in 550 breast cancers from publicly available gene expression datasets (GSE2990, GSE12093, GSE6532). When
treatment with tamoxifen was considered, STAT1 gene expression was nearly predictive of distant metastasis-free survival
(DMFS, log-rank p= 0.067), while STAT3 gene expression was predictive of DMFS (log-rank p,0.0001). Analysis of STAT1 and
STAT3 protein expression in a series of 546 breast cancers also indicated that high expression of STAT3 protein was
associated with improved survival (DMFS, p = 0.006). These results suggest that STAT signaling is important in endocrine
resistance, and that STAT inhibitors may represent potential therapies in breast cancer, even in the resistant setting.
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Introduction
The STAT (Signal Transducer and Activator of Transcription)
family of proteins mediate cytokine and growth factor receptor
signaling, which in turn regulate cell growth, survival, and
differentiation [1–5]. To date, seven STAT proteins have been
identified: STAT1, 2, 3, 4, 5a, 5b, and 6 [1–5]. STAT is activated
by binding of the STAT molecule to activated receptors through
the SH2 domain, which permits dimerization of STATs and their
translocation into the nucleus to regulate downstream genes [1–5].
It is widely agreed that tyrosine phosphorylation (at a site near
residue 700) is required for STAT protein activation and
dimerization and this is activated further by serine phosphoryla-
tion at a site near residue 725 [1–5].
While all seven STAT-family members have been shown to be
expressed in breast cancer cell lines, only STATs 1, 3, 5a, and 5b
are expressed in breast cancer tissues [6,7]. A number of studies
have implicated both oncogenic and tumor suppressor functions
for STAT family members in breast cancer and it seems likely that
individual STAT isoforms have pleiotropic functions at different
stages of disease progression [6,7]. At initiation, STAT3 and
STAT5 are generally considered to be oncogenic while STAT1 is
considered to have a tumor suppressor role [8,9]. STAT3 and
STAT5 have both been implicated in endocrine resistance [10],
particularly in growth factor-stimulated disease, but little is known
of the role of STAT1 in hormonal control. STAT1 and STAT3
activation are frequently reciprocally regulated and perturbation
of their balanced expression or phosphorylation may re-direct
cytokine/growth factor signals from proliferative to apoptotic, or
from inflammatory to anti-inflammatory [11]. The roles of
STAT1 and STAT3 in breast cancer remain controversial since
multiple studies have reported variable results between STAT
isoform expression and clinical outcome, suggesting a degree of
complexity in STAT signaling which is poorly understood. For
example, STAT1 expression has been associated with poor
outcome [12] while increased phospho-STAT1(Tyr701) expres-
sion has been associated with both poor [13] and favourable
survival [14]. Data for STAT3 are similarly variable. Several
reports describes both increased total and phospho-STAT3(-
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Tyr705) being associated with improved survival [15,16], but these
observations contrast with reports of increased phospho-STAT3(-
Tyr705) [17] or total STAT3 being associated with poor survival
[18]. Reduced activation of STAT3 has been identified after
tamoxifen treatment in estrogen receptor alpha (ER) positive
tumors [19], indicating a possible connection between reduced
STAT3 activity and sensitivity to tamoxifen, and the prospect of
enhancement of STAT3 pathway activation in tamoxifen resistant
tumors [10].
In a search for pathways that might influence endocrine therapy
sensitivity and resistance, we initially carried out an unsupervised
interrogation of biochemical signaling pathways using phospho-
protein antibody arrays. STAT1, phospho-STAT1(Tyr701), and
phospho-STAT3(Ser727) were differentially expressed in endo-
crine resistant cell lines relative to parental cells. STAT1
expression is known to be higher in the luminal (ER-positive)
molecular subtype of breast cancer relative to HER2-positive or
triple-negative breast disease [20], but we are not aware of any
reports of its role in endocrine-resistant breast cancer. This study
aimed to investigate further the roles of STAT1 and STAT3 in
endocrine sensitive and resistant breast cancer using both cell line
models and clinical samples from breast cancer patients.
Materials and Methods
Cell lines and culture conditions
MCF-7 cells were cultured in DMEM (phenol red positive,
Gibco) supplemented with 10% heat-inactivated foetal calf serum
(FCS) and penicillin/streptomycin (100 IU/mL) in a humidified
atmosphere of 5% CO2 at 37uC. MCF-7/LCC1 [21] and MCF-
7/LCC9 cells [22] were grown in DMEM (phenol red free, Gibco)
supplemented with 5% double charcoal-stripped serum, glutamine
(0.3 mg/mL), and penicillin/streptomycin (100 IU/mL) in a
humidified atmosphere of 5% CO2 at 37uC.
Cell viability analysis by Sulforhodamine B (SRB) assay
Cells were harvested in log phase, then seeded into 96-well cell
culture plates. MCF-7 cells were washed with PBS and then
transferred to phenol red-free DMEM containing double char-
coal-stripped serum after 48 h, and incubated for a further 48 h.
MCF-7/LCC1 and MCF-7/LCC9 cells were maintained in
double charcoal-stripped medium for 96 h. Cells were then
treated with STAT inhibitors. The STAT1 inhibitor (-)-epigallo-
catechin gallate (EGCG) is a major component of green tea and
was obtained from Sigma Aldrich [23]. The STAT3 inhibitors
Stattic [24,25] and WP1066 [26] were both obtained from
Calbiochem. Stattic is a non-peptide small molecule inhibitor
reported to inhibit STAT3 dimerization by selectively interacting
with the STAT3 SH2 domain [24]. WP1066 has been shown to
inhibit STAT3 signal pathway by down-regulating STAT3 targets
and activating Bax to inhibit STAT3 nuclear localization [26].
Recent data has suggested that Stattic may also interact with
STAT1, so it is feasible that some of its action may be mediated
via STAT1 [27]. After incubation for 5 days with inhibitors, cells
were fixed using 25% cold trichloroacetic acid (Sigma), and
incubated for 1 h at 4uC. Plates then were washed, air-dried, and
stained with sulforhodamine B (Sigma) dye (0.4% solution in 1%
acetic acid). After being washed with 1% acetic acid, Tris buffer
(10 mM, pH 10.5) was added to each well 1 h prior to the optical
density (OD) being read using a Biohit BP800 Microplate reader
at 540 nm.
Protein expression analysis by western blotting
50 ug of protein lysate were electrophoretically resolved on 10%
SDS-PAGE and transferred overnight onto nitrocellulose mem-
branes (Millipore). After transfer, membranes were blocked with
LiCor Odyssey Blocking Buffer for 1 h before probing with the
appropriate primary antibody overnight at 4uC. Primary antibod-
ies used for western blotting were as follows: phospho-STAT1 (Tyr
701) (Cell Signaling), STAT1, phospho-STAT3 (Ser727), STAT3
(all from Eurogentec). All primary antibodies were used at 1:1000
dilution. The membranes were then incubated with fluorescently-
labelled secondary antibodies diluted with Odyssey Blocking
Buffer and then scanned on a Li-Cor Odyssey scanner, and the
fluorescence value (integrated intensity, I.I.) corresponded with the
detected protein expression levels. An a-tubulin (Abcam) antibody
was used as a loading control.
Cell line RNA extraction and two step real-time PCR
Total RNA was extracted from cultured cells using the Qiagen
Mini RNeasy Kit. The concentration and quality of RNA was
assessed using the Agilent RNA 6000 Nano kit on the Agilent
bioanalyser (Agilent Technologies). 1 mg of total RNA from each
individual sample was reverse transcribed using the QuantiTect
Reverse Transcription kit (Qiagen) following the manufacturer’s
protocol. 1 mg total RNA produced 20 mL of cDNA following
reverse transcription. cDNA was quantified using the Rotorgene
(Corbett Research, San Francisco, CA) and the QuantiTect SYBR
Green system (Qiagen) following the manufacturers’ instructions.
The primers for STAT1, STAT3, and b-actin (house-keeping
gene) were obtained from Qiagen. The PCR protocol used was:
initial activation at 95uC for 15 min; 45 cycles of denaturation at
94uC for 15 s; annealing at 56uC for 30 s; extension at 72uC for
30 s, and a final extension at 72uC for 5 min followed by a melt
step from 55uC to 95uC at 0.2uC/s.
Human sample study population and tissue microarray
(TMA) construction
Tissue samples originated from patients with primary breast
carcinomas treated in the Edinburgh Breast Unit from 1999 to
2002. The study was approved by the Lothian Research Ethics
Committee (08/S1101/41) and MREC (04/S0709/16). Ethical
approval 08/S1101/41 authorises the distribution of FFPE
samples and associated linked anonymised data from the
Pathology archive (NHS Lothian) for research as they were
surplus to diagnostic purposes. Axillary lymph node dissection was
performed on all patients as part of surgery for large or high-grade
invasive breast carcinomas. The extracted tissues were then
embedded into a recipient paraffin block in a precisely spaced
array pattern for further analysis. There were 136 primary and
105 nodal cancers available for statistical analysis after TMA
construction, immunostaining, AQUAsition, and AQUAnalysis,
including 65 paired samples. TMAs were constructed in biological
triplicate. A second TMA series was then analysed for which
outcome data were available, consisting of 546 breast cancers.
Immunofluorescence and Automated QUantitative
Analysis (AQUA) of protein expression
This assay was performed using optimized conditions for each
target protein. IHC assays were performed to determine the
optimum working conditions for phospho-STAT1(Tyr701),
STAT1, phospho-STAT3(Ser727), STAT3, phospho-STAT5(-
Tyr694), and STAT5 antibodies (Figure S1 in File S1). The
source of the STAT1 and STAT3 antibodies is described above
while the STAT5 and pSTAT5(Tyr694) were both obtained from
STAT1 Signalling in Breast Cancer
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Cell Signaling. Briefly, sections were heat-treated under pressure
in a microwave for 5 min in optimized antigen retrieval buffer and
incubated with primary antibodies diluted to the optimal dilution
in second primary antibody (mouse anti-cytokeratin, Invitrogen)
diluted in Dako antibody diluents, either for 1 h at room
temperature or overnight at 4uC. Sections were then incubated
with secondary antibodies (including goat anti-mouse Alexa 555
antibody, Invitrogen) for 1 h at room temperature, following by
target signal amplification diluents and the Cy5-tyramide for
visualisation of target protein. Prolong Gold anti-fade reagent with
DAPI (Invitrogen) nuclear visualisation media was applied to the
coverslip. The immunofluorescence results were analysed with the
Automated QUantitative Analysis (AQUA) system. After counter-
staining and cover-slipping, the slides were imaged on the HistoRx
PM-2000 instrument [28] utilizing an automated spot capturing
system. Images were captured using the AQUAsition software and
a 20x objective on the DAPI, CY3, and CY5 channels. For each
immunofluorescence image, the AQUAnalysis software evaluated
the quantity (in AQUA units =Au) of target protein expression
(Cy5-tyramide signal) within the cytoplasm (identified by cytoker-
Table 1. List of proteins and phospho-proteins significantly differentially expressed between LCC1 or LCC9 and parental MCF-7
cell lines.
Phospho Proteins LCC1/MCF-7 LCC9/MCF-7
IKK alpha (Phospho-Thr23) 0.75 0.80
Rel (Phospho-Ser503) 0.72 0.98
Raf1 (Phospho-Ser259) 0.74 1.08
STAT1 (Phospho-Ser701) 1.19 1.18
p53 (Phospho-Ser6) 1.01 1.25
MEK1 (Phospho-Ser221) 1.03 1.26
PDK1 (Phospho-Ser241) 0.88 1.28
STAT1 (Phospho-Ser727) 1.22 1.33
HDAC8 (Phospho-Ser39) 1.00 1.34
JAK2 (Phospho-Tyr1007) 1.08 1.34
BAD (Phospho-Ser112) 1.04 1.35
Caveolin-1 (Phospho-Tyr14) 1.07 1.36
Beta-Catenin (Phospho-Thr41/Phospho-Ser45) 1.14 1.37
TYK2 (Phospho-Tyr1054) 1.12 1.43
Src (Phospho-Tyr418) 1.21 1.43
Met (Phospho-Tyr1349) 1.42 1.43
STAT3 (Phospho-Ser727) 1.28 1.44
JAK1 (Phospho-Tyr1022) 1.23 1.46
I-kappa-B-alpha (Phospho-Ser32/Phospho-Ser36) 1.45 1.52
HSP90B (Phospho-Ser254) 1.23 1.54
Akt (Phospho-Thr308) 1.32 1.59
non-Phospho Proteins LCC1/MCF-7 LCC9/MCF-7
Elk-1 (Ab-383) 0.75 1.12
c-Jun (Ab-73) 1.17 1.25
I-kappa-B-epsilon (Ab-22) 1.04 1.26
ICAM-1 (Ab-512) 1.05 1.26
STAT5A (Ab-694) 1.09 1.28
p70 S6 Kinase (Ab-424) 1.00 1.28
14-3-3 Zeta (Ab-58) 1.07 1.28
NF kappa B-p105/p50 (Ab-337) 1.33 1.29
Raf1 (Ab-259) 1.00 1.29
p27Kip1 (Ab-10) 1.17 1.30
Beta-Catenin (Ab-41/45) 1.02 1.31
JAK2 (Ab-221) 0.98 1.31
JAK1 (Ab-1022) 1.09 1.31
CaMKII (Ab-286) 1.00 1.32
STAT1 (Ab-701) 1.35 1.62
The antibody array comprised 120 matched phospho- and non-phospho-antibodies designed to measure epitopes within major growth factor, cell cycle, and DNA-
damage response pathways (for full list see Table S1 in File S1).
doi:10.1371/journal.pone.0094226.t001
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atin) and nuclei (4,6-diamidino-2-phenylindole, DAPI counter-
staining). Target protein expression was scored only in invasive
cancers and cores containing epithelium ,5% of their total area
were automatically excluded by the software to make sure that
tumors were adequately represented for AQUA scoring [28].
V250 Proteomic analysis
The proteomic microarray analysis was performed by Euro-
gentec (Eurogentec Ltd, Southampton, U.K.) which assessed the
expression levels of 120 phosphorylated and non-phosphorylated
signaling molecules that are known to be dysregulated in cancer.
Protein lysates from the MCF7, MCF-7/LCC1, and MCF-7/
LCC9 cell lines in the presence or absence of 1 nM 17Beta-
estradiol (E2) were analysed using the V250 antibody array
(Eurogentec Ltd, Southampton, U.K.). Each V250 array contains
240 antibodies that bind 120 signaling proteins in either their
phosphorylated or non-phosphorylated forms. A full list of the
antibodies used is shown in Table S1 in File S1. Binding of each
antibody to its target results in an emission fluorescence, whose
intensity is proportional to the level of the target protein. Each
sample was run as six replicates. The intensity score for each
phosphorylated protein was normalized by Eurogentec Ltd
(Southampton, UK) to that of its non-phosphorylated counterpart.
Statistical and bioinformatics analysis
The student’s t-test was used for comparison of two independent
samples. Spearman’s rank correlation coefficient analysis was
performed to detect associations from the immunofluorescence
results. Data on 550 breast cancers from three publicly available
gene expression datasets (GSE2990, GSE12093, GSE6532) were
analysed (obtained from NCBI GEO). The Affymetrix U133A
platform was used for GSE2990 and GSE12093 while the U133A,
U133B, and U133 Plus 2.0 platforms were used for GSE6532.
RMA normalisation was applied [29] and the datasets were
integrated using ComBat to remove dataset-specific batch effects
[30]. We used the software programme, X-Tile, to determine the
optimal cutpoint while correcting for the use of minimum P
statistics [31], which is known to inflate type I error when used
incorrectly [32]. Two methods of statistical correction for the use
of minimal P approach were utilised; the first calculation of a
Monte Carlo P-value and for the second, the Miller-Siegmund
minimal P correction [32]; the minimum P-value, Monte Carlo P-
value, and Miller-Siegmund P-value were all required to be ,0.05
for the cutpoint to be considered valid. Overall survival was
subsequently assessed by Kaplan-Meier analysis with log-rank for
determining statistical significance. The paired T-test was used for
comparing target protein expression differences between the
primary tumor and matched nodes. A p-value of ,0.05 was
considered statistically significant.
Results
STAT1 and STAT3 signaling pathways are differentially
activated in endocrine sensitive and resistant breast
cancer cell lines
In order to establish which pathways might influence estrogen
signaling and endocrine therapy sensitivity and resistance, we
initially carried out an unsupervised interrogation of biochemical
signaling pathways using a phosphoprotein antibody array in
MCF-7 sensitive and resistant breast cancer cell lines. The
antibody array comprised 120 matched phospho- and non-
phospho-antibodies designed to measure key epitopes within the
majority of major growth factor, cell cycle, and DNA-damage
response pathways (for a full list of targets see Table S1 in File S1).
The ER-positive estrogen-dependent MCF-7 breast cancer cell
line was compared with its estrogen-independent but tamoxifen
and fulvestrant-sensitive cell line MCF-7/LCC1 [21] and the fully
estrogen, tamoxifen and fulvestrant-resistant cell line MCF-7/
LCC9 (LCC9; [22]). The most significantly differentially expressed
targets are shown in Table 1 and the complete list is provided in
Table S1 in File S1. Selected components of the STAT, MAPK,
and NFkB pathways were both down- and up-regulated in MCF-
7/LCC1 and MCF-7/LCC9 cell lines, while components of the
mTOR and calcium signaling pathways were down-regulated and
components of the PI3K, heat shock, and HGF signaling pathways
were up-regulated in the resistant cell lines relative to MCF-7
expression. Since five of the top twenty differentially expressed
phosphoprotein targets were components of the JAK/STAT
pathway (STAT1, STAT3, TYK2, JAK1, JAK2) and STAT1 was
the most differentially expressed total protein, we reasoned that
Figure 1. STAT protein (A) and mRNA (B) expression in the MCF-7, MCF-7/LCC1 (LCC1) and MCF-7/LCC9 (LCC9) breast cancer cell
lines. A. MCF-7 cells were double charcoal-stripped for 48 h. Protein lysates were run on a 10% SDS-gel and membranes were probed with phospho-
STAT1(Tyr 701), STAT1, phospho-STAT3 (Ser 727), or STAT3 primary antibodies (1:1000). Column charts show the relative expression level of protein
normalized with loading control (tubulin). Data are presented as relative mean Integrated Intensity (correlated with the fluorescence intensity of
secondary antibody) ratios of target protein over tubulin +/2 SEM from quadruplicate samples. Statistical significance noted for multiple comparision
where *P,0.05, ***P,0.001 (student’s t-test). B. mRNA expression of STAT was measured by two step real time PCR. Total RNA was extracted from
cells charcoal stripped for 48 h. The cDNA was synthesised by reverse transcription, and real time PCR was performed as described in Materials and
Methods. Relative expression of the target gene was normalized to that of Beta-actin. Results are presented as mean 6SD from triplicate samples.
doi:10.1371/journal.pone.0094226.g001
STAT1 Signalling in Breast Cancer
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STAT signaling might be a mediator of endocrine sensitivity and
tamoxifen/fulvestrant resistance in breast cancer, prompting us to
explore this association further.
We confirmed the results of the antibody array using semi-
quantitative western blotting. Total STAT1 expression was
increased in both the MCF-7/LCC1 cell line (,6.4 fold, p,
0.001) and MCF-7/LCC9 cell lines (,7.4 fold, p,0.001)
compared with the parental MCF-7 cell line. Similarly, phos-
pho-STAT1 (Tyr701) expression was increased in both the MCF-
7/LCC1 cell line and MCF-7/LCC9 cell lines compared with the
MCF-7 cell line (Figure 1A) (Figure S2 in File S1). There was a
statistically significant increase in phospho-STAT3 (Ser727)
expression in the MCF-7/LCC9 cell line relative to the MCF-7
cell line (,1.5 fold, p,0.05), while expression was similar between
MCF-7 and MCF-7/LCC1 cells (not significant), and total
STAT3 protein expression was the same in all cell lines.
Figure 2. The effect of STAT inhibitors (A. EGCG, B. WP1066 and C. Stattic) on proliferation of Tamoxifen sensitive and resistant
(MCF-7, MCF-7/LCC1 (LCC1), and MCF-7/LCC9 (LCC9)) cells. All cells were incubated in double charcoal-stripped medium for another 48 h
after seeding and treated with or without inhibitor. O.D values were measured on Day 5. Data were plotted as a mean of O.D values +/2 SD from 6
replicate samples. Asterisks represent significant changes between treatment and no treatment, while hashes represent differences between resistant
cell lines and MCF7. Error bars are standard deviations. Statistical significance noted for treatment groups compared with untreated controls were
#/*P,0.05, ##/**P,0.01, ###/***P,0.001 (ANOVA followed by Tukey-Kramer).
doi:10.1371/journal.pone.0094226.g002
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Since total STAT1 expression levels differed between cell lines,
we sought to establish whether this could be explained by
underlying alterations in gene expression (Figure 1B). qRT-PCR
analysis indicated that mRNA expression of STAT1 was increased
in MCF-7/LCC1 cells (,13 fold) and MCF-7/LCC9 cells (,18
fold), compared with MCF-7 cells, while the difference in STAT3
mRNA expression was of lower magnitude with only a two-fold
increase in expression in both MCF-7/LCC1 and MCF-7/LCC9
cells compared to MCF-7 cells, consistent with protein expression.
Together these data show that STAT1 is differentially expressed in
estrogen insensitive and tamoxifen/fulvestrant resistant cell lines at
the mRNA, total protein, and activated protein level, and might
therefore be a possible target for either single agent therapy or to
overcome endocrine resistance.
STAT inhibitors may be effective therapies, even in the
endocrine-resistant setting
We next investigated the relationship between STAT1 and
STAT3 pathway activation and cell growth in the endocrine-
resistant setting using the STAT1 inhibitor EGCG, and the
STAT3 inhibitors Stattic and WP1066. Cell numbers were
significantly reduced in response to the STAT1 inhibitor EGCG
in the MCF-7/LCC1 and MCF-7/LCC9 cell lines compared to
parental MCF7s (Figure 2), whereas both STAT3 inhibitors Stattic
and WP1066 significantly reduced cell number in all three lines
(Figure 2). STAT3 inhibition might therefore be a useful single
agent or combination therapy in breast cancer while STAT1
inhibition may be more intimately associated with endocrine
treatment failure and a useful therapeutic strategy to target
resistance.
We investigated the effect of STAT inhibition on the inhibitory
effect of tamoxifen within the resistant cell line series. This
experiment was undertaken in the presence of 1 nM E2. Under
these conditions, the inhibitors had similar growth inhibitory
effects against the 3 cell lines. The combination of EGCG, Stattic
or WP1066 and tamoxifen caused a significant enhancement in
inhibition of MCF-7 cells (p,0.05) compared with the STAT
inhibitor alone (Figure 3). This combination treatment also
produced an effect in the MCF-7/LCC1 cell line (Figure 3). In
the MCF-7/LCC9 cell line, there was a minor increase in
inhibition (Figure 3) for the combination treatment, however, a
statistically significant enhancement was only noted for the Stattic
group compared to single STAT inhibitor alone. STAT inhibitors
Figure 3. The effect of STAT inhibitors (EGCG, Stattic, or WP1066) combined with tamoxifen on MCF-7, MCF-7/LCC1 (LCC1), and
MCF-7/LCC9 (LCC9) cells in the presence of estrogen. Cells were grown in charcoal-stripped serum, 48 h prior to treatment and were treated
with control medium containing 1 nM E2, tamoxifen (1 mM)+E2 (1 nM), EGCG (25 mM)+E2 (1 nM), tamoxifen (1 mm)+EGCG (25 mm)+1 nM E2, Stattic
(0.5 mM)+E2 (1 nM), tamoxifen (1 mM)+Stattic (0.5 mm)+E2 (1 nM), WP1066 (2 mM)+E2 (1 nM), tamoxifen (1 mM)+WP1066 (2 mM)+E2 (1 nM) for 5 days.
O.D. values were measured on day 5. Data were plotted as a mean inhibition ratio of O.D. values over untreated control groups +/- SD from 4
replicate samples. Asterisks represent significant changes between combined treatment and the inhibitor alone, while hashes represent differences
between combined treatment and tamoxifen treatment alone. #/*P,0.05, ##/**P,0.01, ###/***P,0.001 (ANOVA followed by Tukey-Kramer).
doi:10.1371/journal.pone.0094226.g003
STAT1 Signalling in Breast Cancer
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therefore can provide a modest additive increase in efficacy over
tamoxifen alone.
Exploration of STAT expression in human breast cancer
samples
The above results suggest that STATs are implicated in breast
cancer resistance. STAT isoform expression was measured in
human breast cancer samples to investigate the associations
between phosphorylated and total STAT protein expression and
clinical parameters. We first analysed paired samples of primary
breast cancers with their associated lymph node metastases to
assess whether and how, STAT isoform expression changed with
disease progression. A series of 136 primary and 105 nodal cancers
were embedded within a TMA and immunofluorescence results
were scored and analysed using Automated QUantitative Analysis
(AQUA). Sixty-five of the primary cancers could be paired with
their associated lymph node specimens. The AQUA scores
represent the expression levels of target proteins in tumor nuclear
or cytoplasmic compartments, using markers (DAPI or cytokeratin
respectively) to help compartmentalise these areas. Representative
immunofluorescence images for STAT protein expression in
human breast cancer and associated nodal disease are shown in
Figure 4. Expression of each STAT/phospho-STAT member was
compared between primary cancer and nodal disease (Table 2).
The mean expression of all the STATs and phospho-STATs, with
the exception of phospho-STAT1(Tyr701) expression (and total
STAT3 in the cytoplasm), were enhanced in their respective nodes
relative to expression in the primary cancer. The most significant
enhancements were exhibited in phospho-STAT3(Ser727) (,1.5
fold) in nuclei, together with STAT1 (,3.1 fold), phospho-
STAT3(Ser727) (,1.8 fold) and STAT5 (,1.5 fold) in cytoplasm.
Next, associations between different STAT isoforms in the same
sample were analysed and associated with previously obtained
data for other markers (ER, PR, HER2, CK5/6, and EGFR) on
these samples. The Spearman’s rank correlation coefficient was
measured for every combination of these STATs or phospho-
STATs expression level in both primary tumors and paired nodes
(Table S2 and S3 in File S1). All phospho-STATs were highly
significantly correlated (nearly all p-values ,0.0001) with each
other in both primary and nodal tumors, among which
cytoplasmic phospho-STAT1(Tyr701) - nuclear phospho-
STAT1(Tyr701), cytoplasmic phospho-STAT3(Ser727) – nuclear
phospho-STAT3(Ser727), and cytoplasmic phospho-STAT5(-
Tyr694) – nuclear phospho-STAT5(Tyr694) had significantly
higher correlation coefficients with r values from 0.74 to 0.95. For
the non-phosphorylated STATs, significant correlations also
existed within each pair with the highest r values from 0.69 to
0.72, except the STAT1 group in the nodal data. The associations
between the STATs and other markers were then analysed. Of
particular note, ER expression was strongly associated with
cytoplasmic expression of STAT1 in primary breast cancers
(p = 0.0003) and in the associated nodes (p = 0.005). Expression of
PR was also very strongly associated with STAT1 in the primary
breast cancers (p,0.0001) although not in nodal disease. Inverse
correlations between EGF receptor expression and both total
STAT1 and phospho-STAT1(Tyr701) were observed in primary
breast cancers (p,0.05) with a marked inverse association for total
STAT1 in paired nodal breast cancers (p,0.0001) (Table S3 in
File S1)
Expression levels of STAT1 and STAT3 transcript were then
analyzed in 550 breast cancers from publicly available gene
expression datasets (GSE2990, GSE12093, GSE6532) (Figure 5A),
and protein expression was measured in an independent cohort of
546 primary breast cancers (Figure 5B). Low expression of STAT3
Figure 4. Comparison of STAT signaling in matched primary and metastatic tissue. Representative immunofluorescence images of
phosphorylated and total STAT1, STAT3 and STAT5 in TMA cores. Blue = DAPI nuclear counterstain, green = cytokeratin tumor mask and red =
target protein.
doi:10.1371/journal.pone.0094226.g004
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was associated with very poor distant metastasis free survival
(DMFS) in patients treated with tamoxifen when measured either
by gene or protein expression (Figure 5; protein expression RR
1.58: 95% CIs 1.1-2.2, p= 0.006). Although there were trends to
poorer outcome for tumors with high expression of STAT1, this
was only of borderline significance. STAT3 expression may
therefore be predictive of outcome in tamoxifen-treated patients.
Discussion
The STAT family of molecules are key regulators of normal
cellular physiology and have important roles in many pathological
conditions [1–5]. Their functions in endocrine-sensitive and
resistant breast cancer are still poorly defined and the published
literature indicates complex roles, particularly for STAT1 and
STAT3. Previous investigations into the roles of the STAT family
in endocrine-resistant breast cancer, especially STAT3 and
STAT5, have shown associations with tumorigenicity, cell-cycle
progression, cell survival, transformation, and angiogenesis [10].
Furthermore, increasing lines of evidence indicated their involve-
ment in the oncogenesis of breast cancer and in resistance to
endocrine therapy; however, there have been few studies on
STAT1 in breast cancer, particularly relating to endocrine
treatment resistance. STAT1 expression has previously been
shown to be associated with resistance to DNA damage and
genotoxic agents which is likely to produce associations with poor
outcome [33,34]. In long-term estrogen exposed MCF-7 cells,
STAT1 expression levels are increased and this again has been
suggested to associate with increased resistance to radiotherapy
and chemotherapy [35]. STAT1 and STAT3 activation have
previously been suggested to be associated with tamoxifen
resistance in MaCa 3366/TAM although expression was not
changed in this model system [36]. To evaluate the roles of
STAT1 and STAT3 further, we used cell line models to study
functional responses in endocrine sensitive and resistant breast
cancer cells and then primary breast cancer samples to evaluate
the associations between expression levels and clinical outcome.
In this study, a 3-stage MCF-7 cell line derived model (MCF-7,
MCF-7/LCC1 and MCF-7/LCC9) [21,22] was used to mimic the
clinical development of endocrine resistance in breast cancer. The
initial proteomic analysis indicated that among some of the major
signaling pathways known to be key in cancer cells, activated
STAT1 and STAT3, were differentially expressed and therefore
potentially interesting signaling candidates in resistant cells. These
differences were first confirmed by protein and mRNA analysis.
The increased expression of STAT1, phospho-STAT1(Tyr701),
and phospho-STAT3(Ser727) in resistant cells compared with
sensitive ones suggested possible roles for STAT1 and STAT3 in
the development of endocrine resistance. Inhibition of both
STAT1 and STAT3 using available small molecule inhibitors
produced growth inhibition. The anti-proliferative effect of EGCG
in the resistant lines suggested that STAT1 might be important in
the development of resistant breast cancer. EGCG has been shown
to have a synergistic action in combination with anti-estrogen
strategies in ER-negative breast cancer cells [37–39] and can
Table 2. Comparison of STAT and phospho-STAT expression between primary breast tumors (BC) and matched lymph node (LN)
disease.
A. Expression in Nuclei
MAX MIN MEAN P val
pSTAT1 BC 1375 358 727 0.02
LN 1381 179 630
pSTAT3 BC 1239 59 329 0.0006
LN 1402 76 502
pSTAT5 BC 172 36 89 0.0002
LN 226 48 112
B. Expression in cytoplasm
MAX MIN MEAN P val
pSTAT1 BC 1005 316 604 0.051
LN 974 173 541
STAT1 BC 720 47 181 ,0.0001
LN 1683 119 568
pSTATT3 BC 676 54 158 ,0.0001
LN 986 77 292
STAT3 BC 2710 386 981 0.0034
LN 1536 346 813
pSTAT5 BC 71 23 46 ,0.0001
LN 163 31 68
STATT5 BC 810 157 303 ,0.0001
LN 1335 143 502
Immunofluorescence data were analysed using AQUA. The maximum, minimum, and mean AQUA values of each protein associated with the expression level are listed
for both nuclear and cytoplasmic expression. A paired t-test was performed to compare whether the difference of expression between primary tumors and nodal
disease was significant, and p values are shown in the tables.
doi:10.1371/journal.pone.0094226.t002
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attenuate growth and invasion in other tamoxifen-resistant breast
cancer cell line models [40]. Our results indicate that it may also
have potential value in endocrine-resistant disease.
Expression levels of both the total and phospho-activated STAT
isoform proteins show complex associations with stage and
outcome in clinical breast cancer samples as evidenced by the
varying results in the literature. This variability is likely to be due
in part to a different balance of subgroups of breast cancers being
investigated in different studies. Our emphasis here was on ER-
positive breast cancer and it is likely that results of ER-positive
disease treated with endocrine therapy may well differ from
population studies with a large percentage of ER-negative disease
patients treated with chemotherapy. Our analysis of clinical breast
cancers indicated that increased total STAT3 expression was
associated with favourable outcome whether examined at the
mRNA or protein level. Our data, based on two independent
cohorts using two different, but complementary technologies,
suggest that STAT3 is predictive for outcome in tamoxifen-treated
patients, consistent with its putative role in hormonally-driven
tumors. This is consistent with the studies of Sonnenblich et al.
[16] and Dollhed-Fillhard et al. [15] which demonstrated
improved survival in phospho-STAT3(Tyr705) expressing breast
cancers. Sonnenblich et al. [16] pointed to the study by Dien et al.
[41] showing that STAT3 upregulates tissue inhibitor of
metalloproteinase-1 (TIMP1) expression, which decreases inva-
siveness of breast cancer cells. Of interest, STAT3 phosphoryla-
tion has previously been shown to be associated with local regional
node involvement but not with distant metastases [42]. Our data
suggest increased levels in local lymph nodes relative to the
primary breast cancers but this may not be the same in distant
metastasis. Total STAT1 expression demonstrated borderline
association with prognosis, with higher mRNA expression being
associated with poorer outcome. This was however, not supported
by the protein expression data. The results of studies investigating
the prognostic and predictive significance of STAT1 expression
are variable. A microarray study evaluated STAT1 expression in a
large series of breast cancers and expression was observed in 21%
of 923 breast cancers with its presence being associated with poor
survival [12]. However in a smaller study of 102 breast cancers, no
association with outcome was observed [43]. In a study of 47
premenopausal and 118 postmenopausal breast cancer patients,
tumor expression of phosphorylated STAT1(Tyr 701) was
reported to correlate with poor survival in premenopausal women,
but not in postmenopausal women [13]. In contrast, in a study
reported by Widschwendter et al., increased STAT1 activation
and phosphorylation were associated with favourable outcome
[14]. Both studies investigated phospho-STAT1(Tyr701), but used
different antibodies perhaps contributing to the different results.
Therefore, while associations are being identified between STAT1
expression and outcome, the results are conflicting. It is interesting
Figure 5. STAT expression and prognosis. Gene (A) and protein (B) expression of STAT1 and STAT3 in primary breast cancer (blue = low,
green= high). Optimal cut-points were determined using the x-tile program while correcting for the use of minimum P statistics (31). Low STAT3
expression is associated with very poor outcomes for patients treated with tamoxifen (protein expression STAT3 high (78% fifteen-year survival) vs.
STAT3 low (68% five year survival).
doi:10.1371/journal.pone.0094226.g005
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that STAT5 is also reported to be associated with favourable
outcome in breast cancer for both total STAT5 [44] and nuclear
phospho-STAT5 [45,46] yet, like STAT3, this is considered to
have a pro-oncogenic role in early disease development [8,9].
It is feasible that STAT1 and STAT3 may have differing roles
in different breast cancer subgroups dependent on whether they
are hormonally or growth factor-driven. Hence, functionality may
vary between endocrine-sensitive and endocrine-resistant ER-
positive breast cancer and ER-negative disease. Associations
between STAT1 and ER expression have been reported [13],
and in our study, we observed highly significant correlations
between STAT1 and ER expression and an inverse correlation
with EGF receptor expression. Therefore, if ER-positive (luminal
A type) cancers have a higher level of expression of STAT1 than
other breast cancer types [19], they may represent the best target
group for STAT1-targeted approaches.
In conclusion, these results indicate that STAT1 expression and
activation can be increased in endocrine-resistant breast cancer
and STAT1 inhibitors may be effective in resistant cells. In clinical
samples, STAT isoform expression can increase between primary
cancer and their matched lymph node metastases, suggesting a
link with disease progression. These results indicate that STAT1
may represent a viable target in endocrine-resistant disease and
merit further studies with STAT1 targeted inhibitors.
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